A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

NCT00001096 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MN rgp120/HIV-1 and A244 rgp120/HIV-1
BIOLOGICAL: QS-21
BIOLOGICAL: rgp120/HIV-1MN

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)